📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-17 16:40
666 analysed today
666
Today
133,555
All-time analysed
40,122
Positive
6,284
Negative
79,331
Neutral
7,750
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
10 announcements match the current filters (relevance ≥ 5).
CARE Upgrades Fermenta Biotech's Long-Term Rating to 'BBB+' on Rs 172.98 Cr Bank Facilities
CARE Ratings Limited has upgraded Fermenta Biotech's credit ratings across its bank facilities totalling Rs 172.98 crore. The rating for long-term bank facilities was upgraded to 'CARE BBB+; Stable' from 'CARE BBB; Stable', with the rated limit enhanced to Rs 166.73 crore from Rs 118.94 crore. Short-term bank facilities of Rs 6.25 crore were upgraded to 'CARE A2' from 'CARE A3+'. The upgrade reflects an improved credit risk profile relative to the company's existing debt of Rs 113 crore and net worth of Rs 406 crore.
Confidence: HIGH
What changedCARE Ratings upgraded Fermenta Biotech's long-term rating from BBB to BBB+ (Stable) and short-term rating from A3+ to A2 on total bank facilities of Rs 172.98 crore.
Why it mattersThe upgrade signals improved creditworthiness, potentially lowering borrowing costs and expanding financial flexibility for operational and capital requirements.
Total rated bank facilities: Rs 172.98 croreLong-term bank facilities: Rs 166.73 crore (enhanced from Rs 118.94 crore)Short-term bank facilities: Rs 6.25 croreTotal rated facilities vs TTM revenue: ~34.5%
📅 Short termPositive for market sentiment, though direct immediate P&L impact will depend on loan renegotiations with lenders.
📈 Long termEnhances the company's funding access and cost efficiency as it scales operations on a low debt-to-equity base (0.28x).
⚠ Risk flags
- Potential increase in interest burden if enhanced limits of Rs 166.73 crore are heavily drawn
Key Highlights
Long-term bank facilities upgraded to CARE BBB+; Stable from CARE BBB; Stable
Long-term bank facility limits enhanced to Rs 166.73 crore from Rs 118.94 crore
Short-term bank facilities of Rs 6.25 crore upgraded to CARE A2 from CARE A3+
Total rated bank facilities aggregate to Rs 172.98 crore
👀 What to Watch
Track whether the credit rating upgrade leads to lower borrowing costs in upcoming quarterly finance costs, and monitor debt utilization from the enhanced facilities.
Fermenta Biotech Approves ₹3.75 Dividend and ₹100 Cr Related Party Transaction at 74th AGM
Fermenta Biotech concluded its 74th Annual General Meeting, where shareholders approved a final dividend of ₹3.75 per share (75% of face value) for FY26. A key resolution passed was the approval for material related party transactions with its subsidiary, Fermenta USA LLC, for an aggregate value up to ₹100 crore. This transaction limit is significant, representing approximately 19% of the company's TTM revenue of ₹525 crore. Additionally, the company authorized a commission of up to 1% of net profits for non-executive directors.
Confidence: HIGH
What changedShareholders have formally ratified the FY26 financial statements, the dividend payout, and established a ₹100 crore ceiling for transactions with the US subsidiary.
Why it mattersThe approval of a ₹100 crore transaction limit with the US subsidiary indicates the company's expectation of significant business volume in the North American market, which is critical for its pharmaceutical exports.
Dividend per share: ₹3.75RPT Limit (Fermenta USA): ₹100 croreRPT vs TTM Revenue: ~19%Director Commission Limit: 1% of net profitsDividend Payment Deadline: August 21, 2026
📅 Short termThe stock may see minor activity around the dividend payment date of August 21, but the announcement is largely procedural and expected.
📈 Long termThe structural focus remains on the company's ability to maintain its 19% OPM while scaling international operations through its US subsidiary.
⚠ Risk flags
- Related party transactions with subsidiary (₹100 crore limit)
Key Highlights
Approved a final dividend of ₹3.75 per equity share for the financial year ended March 31, 2026.
Authorized material related party transactions with Fermenta USA LLC up to a limit of ₹100 crore.
Approved commission for Non-Executive Directors up to an aggregate of 1% of net profits.
Confirmed dividend payment will be completed on or before August 21, 2026.
Re-appointed Ms. Rajeshwari Datla as a Non-Executive Director following her retirement by rotation.
👀 What to Watch
Investors should monitor the quarterly revenue contribution from the US subsidiary to see if the ₹100 crore transaction limit translates into actual sales growth.
₹110 Cr Capex Approved for Vitamin D3 Expansion; FY26 Revenue Hits Record ₹548 Cr
Fermenta Biotech reported a record FY26 revenue of ₹548 Cr, up 14% YoY, with core EBITDA (excluding real estate) rising 44% to ₹120 Cr. The Board has approved a significant ₹110 Cr capex for expanding plant-source Vitamin D3 and biocatalysis enzymes at the Dahej facility, representing ~21% of TTM revenue. While PAT fell to ₹70 Cr from ₹76 Cr, the prior year was inflated by a ₹45 Cr one-off real estate gain, indicating improved core profitability. Free cash flow tripled to ₹62 Cr, providing a strong cushion for the planned expansion.
Confidence: HIGH
What changedThe company has transitioned from a recovery phase to a growth phase, backed by a major capex approval and a strategic shift toward high-value, patent-protected plant-source vitamins.
Why it mattersThe ₹110 Cr investment is a significant capacity expansion (21% of revenue) that targets higher-margin specialized segments, potentially reducing the company's reliance on commodity-grade Vitamin D3.
FY26 Revenue: ₹548 CrApproved Capex: ₹110 CrCapex vs TTM Revenue: 20.95%Free Cash Flow (FY26): ₹62 CrCore EBITDA Growth: 44%Net Debt Reduction: roughly halved
📅 Short termPositive sentiment is expected as the AGM presentation highlights record core performance and a clear roadmap for high-value capacity expansion.
📈 Long termStructural significance is high; if the ₹110 Cr capex successfully commercializes plant-source D3 and enzymes, it could lead to a margin-led re-rating over the next 2-3 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk of the ₹110 Cr capex project
- Product concentration in Vitamin D3
- Regulatory compliance for new European market entry
Key Highlights
Approved ₹110 Cr capex for plant-source Vitamin D3, Calcifediol, and biocatalysis enzymes at Dahej
Core EBITDA (excluding real estate) grew 44% to ₹120 Cr in FY26
Free cash flow tripled to ₹62 Cr, funding the stepped-up capex requirements
Secured EDQM CEP for Vitamin D3 100 SD, opening European pharmaceutical markets
Granted Indian process patent for VITADEE Green® (plant-source Vitamin D3)
👀 What to Watch
Monitor the execution timeline of the ₹110 Cr Dahej expansion and the commercial ramp-up of plant-source Vitamin D3 in the European market following the CEP approval.
Fermenta Biotech Q1FY27: PAT Drops 56% YoY to ‹9.5 Cr; Human Nutrition Recovers 24% QoQ
Fermenta Biotech reported a weak Q1FY27 on a YoY basis, with PAT declining 56% to ‹9.5 Cr, largely due to a high base in Q1FY26 which included ‹4.3 Cr of non-recurring income. Revenue fell 13% YoY to ‹126.2 Cr, though the core Human Nutrition segment showed resilience with a 24% sequential (QoQ) revenue growth. Animal Nutrition remains a major headwind, with volumes down 52% QoQ and realizations dropping 40% YoY. The company is pivoting towards India, which now accounts for 47% of revenue compared to 35% a year ago.
Confidence: HIGH
What changedThe company experienced a sharp profitability contraction YoY due to a high base and weak animal nutrition pricing, but saw a sequential volume recovery in its largest segment (Human Nutrition).
Why it mattersThe results highlight the volatility of the Vitamin D3 market; the company's shift toward value-added products like Calcifediol and plant-based D3 is critical to reducing this cyclicality.
Q1FY27 PAT: ‹9.5 CrHuman Nutrition QoQ Growth: 24%Animal Nutrition Realization Change: -40% YoYDahej Capex Value: ‹110 CrCapex vs Net Worth: 27.1%India Revenue Share: 47%
📅 Short termThe stock may face pressure due to the significant YoY decline in PAT and EBITDA margins, despite the sequential improvement in human nutrition.
📈 Long termThe structural shift toward the ‹110 Cr Dahej expansion and high-margin products like Calcifediol could re-rate the business if execution leads to margin expansion beyond the current 19% OPM.
⚠ Risk flags
- Severe pricing pressure in Animal Nutrition
- Rising employee costs ahead of revenue generation
- High base effect volatility
Key Highlights
PAT fell 56% YoY to ‹9.5 Cr, impacted by the absence of non-recurring insurance and real estate income present in Q1FY26.
Human Nutrition revenue grew 24% QoQ to ‹76.5 Cr, driven by an 18% increase in segment volumes.
Animal Nutrition realizations crashed 40% YoY, leading to a 41% YoY revenue decline in that segment to ‹12.6 Cr.
Employee costs rose to 19% of revenue versus 16% in FY26, reflecting hiring for the upcoming Dahej facility scale-up.
India market contribution increased to 47% of consolidated revenue, up from 35% in the same quarter last year.
👀 What to Watch
Monitor the commercialization timeline of Calcifediol and the market uptake of VITADEE Green following its July 2026 FSSAI approval. Investors should watch if the sequential recovery in Human Nutrition can offset the continued pricing pressure in the Animal Nutrition segment.
Fermenta Biotech Q1FY27 PAT drops 56% YoY to ₹9.5 Cr; Human Nutrition volumes up 18% QoQ
Fermenta Biotech reported a weak Q1FY27 with consolidated revenue at ₹126.2 cr, down 13% YoY, and PAT falling 56% to ₹9.5 cr. The decline was primarily driven by a 40% drop in Vitamin D3 Animal Nutrition realizations and a high base effect from non-recurring insurance and real estate income in Q1FY26. However, Human Nutrition volumes grew 18% QoQ, and the India market share increased to 47% of revenue. A key positive is the FSSAI approval for VITADEE Green® received in July 2026, targeting the domestic vegetarian market.
Confidence: HIGH
What changedThe company faced a sharp decline in profitability due to pricing pressure in the animal nutrition segment and the absence of one-off insurance/real estate gains seen in the previous year.
Why it mattersThe results highlight a strategic shift toward the domestic Indian market and human nutrition, which now accounts for 61% of revenue, potentially reducing future volatility from global animal feed cycles.
Q1FY27 Consolidated Revenue: ₹126.2 crQ1FY27 Consolidated PAT: ₹9.5 crAnimal Nutrition Realization Change: -40% YoYHuman Nutrition Volume Growth: 18% QoQIndia Revenue Share: 47%Revenue vs TTM Revenue: 24.03%
📅 Short termThe stock may face downward pressure in the short term due to the 56% PAT decline and margin contraction, despite the management's focus on volume growth.
📈 Long termStructural growth depends on the successful scaling of the Dahej plant-based Vitamin D3 capacity and the penetration of VITADEE Green® in the Indian vegetarian market.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Continued pricing pressure in the Animal Nutrition segment
- High base effect from non-recurring income in previous periods
- Execution risk for new capacity at Dahej
Key Highlights
Consolidated PAT fell 56% YoY to ₹9.5 crore, impacted by a 40% drop in Animal Nutrition realizations.
Human Nutrition volumes increased 18% QoQ, contributing ₹76.5 crore to revenue (61% of total).
India's share of consolidated revenue rose to 47% in Q1FY27 from 35% in the previous year.
FSSAI approval for VITADEE Green® was received on July 6, 2026, for use in health supplements and food fortification.
Animal Nutrition revenue declined 41% YoY to ₹12.6 crore due to weak pricing and volume discipline.
👀 What to Watch
Monitor the commercialization timeline of the Dahej plant-based Vitamin D3 capacity and the market uptake of VITADEE Green® following FSSAI approval. Watch for stabilization in Animal Nutrition realizations, which significantly dragged down margins this quarter.
Fermenta Biotech Approves Q1 FY27 Results; TTM Revenue Stands at ₹525 Cr
Fermenta Biotech has approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The statutory auditors, M/s. SRBC & Co. LLP, issued a limited review report with an unmodified opinion, suggesting no major accounting discrepancies. These results follow a fiscal year (FY26) where the company reported a revenue of ₹525 Cr and a PAT of ₹71 Cr. Investors should monitor if the company can improve its operating margins, which stood at 19% in FY26 compared to 25% in FY25.
Confidence: HIGH
What changedThe company has formally released its financial performance data for the first quarter of the 2026-27 fiscal year.
Why it mattersAs the first quarter of the new fiscal year, these results set the tone for FY27, especially after a year of margin compression (OPM fell from 25% to 19% in FY26).
TTM Revenue: ₹525 CrTTM PAT: ₹71 CrMarket Cap: ₹1629 CrPromoter Holding: 64.08%Debt to Equity: 0.28
📅 Short termThe stock price may react based on how the Q1 FY27 numbers compare to the ₹22 Cr PAT reported in the same quarter last year.
📈 Long termThe long-term focus remains on the company's ability to scale its pharmaceutical business while recovering operating margins toward historical highs of 25%.
⚠ Risk flags
- Margin volatility (OPM dropped from 25% in FY25 to 19% in FY26)
- High recent price run-up (95.6% in 3 months) may lead to profit booking if results are not exceptional
Key Highlights
Board meeting conducted on August 11, 2026, between 11:00 a.m. and 01:10 p.m.
Unaudited financial results approved for the quarter ended June 30, 2026
Statutory auditors M/s. SRBC & Co. LLP issued an unmodified opinion on the results
Company maintains a promoter holding of 64.08% as of the latest reporting period
TTM revenue of ₹525 Cr and TTM PAT of ₹71 Cr provide the baseline for current performance
👀 What to Watch
Investors should compare the Q1 FY27 revenue and operating margins against the Q1 FY26 revenue of ₹136 Cr and PAT of ₹22 Cr to determine if the growth trajectory is sustaining.
Fermenta Biotech Approves Q1 FY27 Results; Auditors Issue Unmodified Opinion
Fermenta Biotech's board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, in a meeting held on August 11, 2026. The statutory auditors, SRBC & Co. LLP, issued a limited review report with an unmodified opinion, indicating no significant accounting concerns. While the specific quarterly figures were not detailed in the cover letter, the company enters this period with a TTM revenue of ₹525 Cr and a TTM PAT of ₹71 Cr. Investors should compare the full results against the ₹136 Cr revenue and ₹22 Cr net profit recorded in the same quarter of the previous year (June 2025).
Confidence: MEDIUM
What changedThe company has finalized and received auditor clearance for its financial performance during the April-June 2026 period.
Why it mattersThis is the first quarterly update for the new fiscal year, providing a baseline for growth expectations in a year where the stock has already seen a 93% price return over the last three months.
TTM Revenue: ₹525 CrTTM PAT: ₹71 CrMarket Cap: ₹1597 CrDebt-to-Equity Ratio: 0.28Meeting Duration: 130 minutes
📅 Short termThe stock may see volatility as the market digests the specific growth and margin numbers relative to the previous year's high base (₹136 Cr revenue in June 2025).
📈 Long termFocus remains on the company's ability to sustain its 20% ROCE and whether it can return to the 25% margin levels seen in FY25.
Key Highlights
Board meeting conducted on August 11, 2026, between 11:00 a.m. and 01:10 p.m.
Statutory auditors M/s. SRBC & Co. LLP issued an unmodified opinion on the financial results.
Results approved for the first quarter of FY27, ending June 30, 2026.
Company maintains a TTM Operating Profit Margin of 19.0% as per latest available context.
👀 What to Watch
Review the detailed P&L statement to check if the operating profit margin has stabilized or improved from the 19% reported in FY26, compared to 25% in FY25.
Fermenta Biotech to list 2.94 crore equity shares on NSE effective August 04, 2026
Fermenta Biotech Limited has received approval to list its 2,94,30,987 equity shares on the National Stock Exchange (NSE) starting August 04, 2026. The company, which is currently listed on the BSE, will trade under the symbol 'FERMENTA'. This move is expected to enhance the stock's liquidity and visibility among institutional and retail investors. The company currently has a market capitalization of ₹1,355 crore and TTM revenue of ₹525 crore.
Confidence: HIGH
What changedThe company is expanding its exchange presence by listing on the National Stock Exchange (NSE) in addition to its existing listing on the BSE.
Why it mattersListing on the NSE is a significant milestone for a mid-cap company (₹1,355 Cr market cap) as it generally leads to higher trading liquidity, better visibility, and potential inclusion in broader market indices.
Total shares to be listed: 2,94,30,987Face value per share: ₹5Listing date: August 04, 2026Market Capitalization: ₹1355 CrTTM Revenue: ₹525 Cr
📅 Short termExpect a potential increase in trading volumes and minor volatility as the stock begins trading on the NSE platform on August 4.
📈 Long termStructural positive for the stock's liquidity profile; facilitates easier entry/exit for larger institutional investors over the coming quarters.
Key Highlights
2,94,30,987 equity shares of ₹5 face value to be listed on NSE
Listing and admission to dealings effective from August 04, 2026
Company assigned the NSE trading symbol: FERMENTA
Follows the initial intimation regarding NSE listing dated June 16, 2026
👀 What to Watch
Investors should monitor the transition of trading volumes from BSE to NSE starting August 4. While business fundamentals remain unchanged, the dual listing typically improves price discovery and accessibility for institutional funds.
Fermenta Biotech Proposes ₹3.75 Dividend and ₹100 Cr Related Party Transaction Limit
Fermenta Biotech has issued a notice for its 74th AGM scheduled for August 11, 2026. The company has proposed a dividend of ₹3.75 per share (75% of face value), representing a yield of approximately 0.87% at current prices. A significant agenda item is the approval of material related party transactions with its US step-down subsidiary, Fermenta USA LLC, for up to ₹100 crore. This transaction limit is substantial, representing roughly 19% of the company's TTM revenue of ₹525 crore.
Confidence: HIGH
What changedThe company is seeking shareholder approval for its annual dividend payout and establishing a significant financial headroom for transactions with its US-based step-down subsidiary.
Why it mattersThe ₹100 crore RPT limit indicates that the US subsidiary is a major component of the company's operational strategy. The dividend payout confirms the company's ability to return capital despite a moderate debt-to-equity ratio of 0.28.
Proposed Dividend: ₹3.75 per shareRPT Limit (Fermenta USA LLC): ₹100 CrRPT Limit vs TTM Revenue: 19.04%Director Commission Limit: 1% of net profitCost Auditor Remuneration: ₹2,75,000
📅 Short termThe stock may see minor interest due to the dividend announcement, though the yield is relatively modest at under 1%.
📈 Long termThe focus remains on the execution and revenue contribution from the US subsidiary, as evidenced by the large related party transaction mandate.
⚠ Risk flags
- Significant related party transaction limit (₹100 Cr) with a step-down subsidiary.
- Re-appointment of a director above the age of 75 requires a special resolution.
Key Highlights
Proposed dividend of ₹3.75 per equity share of ₹5 face value for FY26.
Seeking approval for related party transactions with Fermenta USA LLC up to an aggregate of ₹100 crore.
Special resolution for the continuation of Ms. Rajeshwari Datla (age 76) as a Non-Executive Director.
Proposed commission for Non-Executive Directors up to 1% of net profits for FY26.
Ratification of ₹2,75,000 remuneration for Cost Auditors for the financial year ending March 31, 2027.
👀 What to Watch
Investors should monitor the AGM voting results, particularly the approval of the ₹100 crore transaction limit with the US subsidiary, to understand the scale of international operations and governance oversight.
₹548 Cr Revenue & ₹110 Cr Capex: Fermenta Biotech FY26 Annual Report Highlights
Fermenta Biotech reported a record consolidated revenue of ₹548 Cr for FY26, a 14% YoY increase driven by strong Vitamin D3 demand. The company is pivoting towards patented innovation with a new process patent for plant-source Vitamin D3 and a ₹110 Cr capex plan at Dahej, representing ~21% of TTM revenue. While reported PAT dipped slightly to ₹70 Cr from ₹76 Cr due to lower real-estate income, core EBITDA grew 44% to ₹120 Cr. The balance sheet strengthened with net debt halving and cash flow from operations more than doubling to ₹93 Cr.
Confidence: HIGH
What changedTransition from a process-led manufacturer to a patented innovator in the Vitamin D3 space with a significant capacity expansion underway.
Why it mattersThe ₹110 Cr capex targets high-growth segments like vegan Vitamin D3 and enzymes for the PLI-backed penicillin industry, diversifying revenue beyond traditional APIs and improving margin profiles.
FY26 Consolidated Revenue: ₹548 CrDahej Capex Program: ₹110 CrCapex vs TTM Revenue: ~21%Core EBITDA Growth: 44%Cash Flow from Operations: ₹93 CrFY26 Net Profit: ₹70 Cr
📅 Short termPositive sentiment is expected as the annual report confirms strong core operating momentum and a clear roadmap for high-value product launches.
📈 Long termThe structural shift towards patented plant-based Vitamin D3 and enzymes for the domestic penicillin industry could significantly re-rate the business over the next 2-3 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk of the ₹110 Cr capex program
- Volatility in global Vitamin D3 prices
- Regulatory compliance for new clinical therapeutic lines
Key Highlights
Consolidated revenue reached a record ₹548 Cr in FY26, up 14% from ₹481 Cr in FY25.
Board approved a ₹110 Cr capex program at Dahej for plant-based Vitamin D3, Calcifediol, and enzymes.
Core EBITDA (excluding real estate) rose 44% to ₹120 Cr, reflecting strong operating leverage.
Cash flow from operations more than doubled to ₹93 Cr from ₹41 Cr in the previous year.
Secured Indian process patent for plant-source Vitamin D3 in September 2025.
👀 What to Watch
Monitor the execution timeline of the ₹110 Cr Dahej expansion and the commercial ramp-up of the newly patented plant-based Vitamin D3 products.
